Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Xcancer LLC

Neither a doctor nor a teaching hospital

Research payments

$1,291,699

455 payments

Through program year 2024, Xcancer LLC is reported as receiving $1,291,699 in research payments, across 455 payments.

By program year

4 rows
Year Kind Amount Payments
2024 Research $95,724 8
2023 Research $216,398 79
2022 Research $605,653 220
2021 Research $373,923 148

Breakdown

Who paid Research payments · program years 2021–2024
  1. BeiGene, Ltd. $857,708 345 payments
  2. Epizyme, Inc., $109,934 33 payments
  3. Daiichi Sankyo Inc. $94,216 4 payments
  4. Eli Lilly and Company $83,200 8 payments
  5. G1 Therapeutics, Inc. $53,500 32 payments
  6. Veru Inc. $43,259 11 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $27,789 18 payments
  8. Exelixis Inc. $21,593 3 payments
  9. Stemline Therapeutics Inc. $500 1 payment
Studies the money was for Research payments · program years 2021–2024
  1. RATIONALE-301: A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma $216,852 131 payments
  2. A Phase 2, Multicenter, Randomized, 3-Arm, Open-Label Study to Investigate the Preliminary Efficacy and Safety of the Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Plus Tislelizumab Plus Concurrent Chemoradiotherapy in Patients With Untreated Lim $203,595 52 payments
  3. Phase 3, Randomized, Open Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus cCRT Followed by Tislelizumab Versus cCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer $187,237 68 payments
  4. AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC) $119,565 30 payments
  5. Ds8201-A-U302 $90,216 2 payments
  6. Emonarcher: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, Her2+ Early Breast Cancer Who Have Completed Adjuvant Her2-Targeted Therapy $83,200 8 payments
  7. A Phase 1B/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer $56,984 21 payments
  8. A Phase 3, Randomized, Double-Blind Study of COSELA or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE-2) $53,500 32 payments
  9. A Phase 1B/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide Or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer $52,951 12 payments
  10. AdvanTIG-205 $43,370 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record